DPP4 and metabolic dysfunction-associated steatohepatitis: In contrast, anagliptin treatment does not appear to affect serum parameters related to diabetes and dyslipidemia in our NASH model, whereas it markedly inhibits DPP-4 activity and increased active GLP-1 levels in the serum.